Pyrazolo-triazolo-pyrimidine A2a Antagonists for CNS Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for central nervous system diseases such as Parkinson's disease and attention deficit hyperactivity disorder lack effective and selective adenosine A2a receptor antagonists with minimal side effects.
Innovation Solution
Development of substituted pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine compounds that act as adenosine A2a receptor antagonists, which can be administered alone or in combination with other agents to treat various neurological disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for central nervous system diseases are used, then therapeutic effects are achieved, but side effects increase and selectivity is reduced
Solution Approach 1:
The patent applies local quality by designing a molecule with distinct functional regions: the pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine core provides A2a receptor selectivity, while specific substituent groups (R1-R6) modulate affinity and selectivity. This localized functional differentiation enables the compound to selectively target A2a receptors in the basal ganglia without affecting other adenosine receptor subtypes, thereby achieving therapeutic efficacy with reduced side effects.
Solution Approach 2:
The patent employs parameter changes by systematically varying the chemical structure parameters of the pyrazolo-triazolo-pyrimidine scaffold, including different substituent groups (aryl, heteroaryl, cycloalkyl), their positions, and their configurations. This structure-activity relationship optimization allows fine-tuning of receptor binding affinity and selectivity, enabling the development of compounds with improved therapeutic profiles for Parkinson's disease and other CNS disorders.
2Reliability
If adenosine A2a receptor antagonists are developed, then selectivity for A2a receptors increases, but manufacturing complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the complex pyrazolo-triazolo-pyrimidine structure into modular synthetic components that can be assembled through sequential reactions. The core triazolo-pyrimidine ring can be constructed from separately prepared intermediates, and substituent groups can be introduced at different stages of synthesis. This modular approach facilitates methodical development of synthetic routes while maintaining molecular complexity required for A2a selectivity.
Solution Approach 2:
The patent employs universality by designing a versatile pyrazolo-triazolo-pyrimidine core structure that serves multiple functions: it provides the necessary A2a receptor binding affinity, maintains selectivity against other adenosine receptor subtypes, and offers multiple points for substituent attachment. This multi-functional core enables a single synthetic platform to generate multiple analogs with different pharmacological profiles, reducing the need for entirely separate synthesis pathways.
Data Source
AI summary
Compounds having the structural formula Ior a pharmaceutically acceptable salt thereof, whereinR is optionally substituted phenyl, furanyl, thienyl, pyridyl, pyridyl N-oxide, oxazolyl or pyrrolyl, or cycloalkenylR1, R2, R3, R4 and R5 are H, alkyl or alkoxyalkyl; andZ is optionally substituted aryl or heteroaryl are disclosed. Also disclosed is the use of compounds of formula I in the treatment of central nervous system diseases, in particular Parkinson's disease, alone or in combination with other agents for treating Parkinson's disease, and pharmaceutical compositions comprising them.